-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Qilu Pharmaceutical entered the administrative examination and approval stage with imatinib mesylate tablets reported for production in category 4 imitations.
Source: official website of the State Drug Administration
Imatinib mesylate is a Bcr-Abl tyrosine kinase inhibitor developed by Novartis.
According to data from Meinenet, in 2020, the total sales of imatinib mesylate tablets in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and Chinese urban entity pharmacies will be close to 25 100 million yuan.
At present, 8 companies have submitted applications for imatinib mesylate tablets in the 4 categories.
Since 2021, Qilu Pharmaceutical has been approved for marketing
Source: Meinenet MED2.
According to data from Minai.
Source: Minei.